The Progesterone Antagonist RU 486

Lynnette K. Nieman, Teresa M. Choate, George P. Chrousos, David L. Healy, Martin Morin, David Renquist, George R. Merriam, Irving M. Spitz, C. Wayne Bardin, Etienne Emile Baulieu, Donald (Lynn) Loriaux

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Since progesterone supports endometrial nidation of the fertilized ovum, a progesterone antagonist would theoretically block this process and thus have contraceptive potential. We have explored the ability of RU 486, a newly developed competitive progesterone antagonist, to function as a contraceptive agent. A single oral dose of 10 mg per kilogram of body weight given in the midluteal phase consistently induced menses within 72 hours in women with normal cycles and no risk of pregnancy. Bleeding was not prevented by administration of human chorionic gonadotropin in the midluteal phase. This suggested that giving a single dose of RU 486 late in the menstrual cycle might be an effective contraceptive strategy. This concept was tested in monkeys. When given to rhesus females on day 25 of the cycle, a single intramuscular dose of RU 486 (5 mg per kilogram) prevented pregnancy. The vehicle-treated control animals had a 28 percent pregnancy rate (P<0.05 by chi-square analysis). No side effects were noted in women or monkeys. These data suggest that a progesterone antagonist such as RU 486 has the potential to be an effective, safe, and convenient contraceptive agent. Further work will be necessary to assess the safety of long-term monthly administration and to define the optimal dose and time of administration in women. (N Engl J Med 1987; 316:187–91.), A SAFE, convenient, and effective method of fertility control has been sought for centuries. No currently available form of birth control, however, is ideal. Oral steroidal contraceptives must be taken daily for maximal effectiveness, and unacceptable side effects increase both with age and with tobacco use.1,2 Intrauterine devices are associated with pelvic inflammatory disease and subsequent decreased fertility.3,4 Barrier methods (condom and diaphragm), although largely free of untoward side effects, have high failure rates related mainly to poor compliance.5 Since progesterone is necessary for nidation of the fertilized ovum, a progesterone antagonist, in theory, could interrupt the hormonal support of…

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalNew England Journal of Medicine
Volume316
Issue number4
DOIs
StatePublished - Jan 22 1987
Externally publishedYes

Fingerprint

Mifepristone
Progesterone
Contraceptive Agents
Zygote
Contraception
Haplorhini
Pelvic Inflammatory Disease
Pregnancy
Intrauterine Devices
Menstruation
Condoms
Chorionic Gonadotropin
Pregnancy Rate
Menstrual Cycle
Oral Contraceptives
Diaphragm
Tobacco
Body Weight
Hemorrhage
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nieman, L. K., Choate, T. M., Chrousos, G. P., Healy, D. L., Morin, M., Renquist, D., ... Loriaux, D. L. (1987). The Progesterone Antagonist RU 486. New England Journal of Medicine, 316(4), 187-191. https://doi.org/10.1056/NEJM198701223160404

The Progesterone Antagonist RU 486. / Nieman, Lynnette K.; Choate, Teresa M.; Chrousos, George P.; Healy, David L.; Morin, Martin; Renquist, David; Merriam, George R.; Spitz, Irving M.; Bardin, C. Wayne; Baulieu, Etienne Emile; Loriaux, Donald (Lynn).

In: New England Journal of Medicine, Vol. 316, No. 4, 22.01.1987, p. 187-191.

Research output: Contribution to journalArticle

Nieman, LK, Choate, TM, Chrousos, GP, Healy, DL, Morin, M, Renquist, D, Merriam, GR, Spitz, IM, Bardin, CW, Baulieu, EE & Loriaux, DL 1987, 'The Progesterone Antagonist RU 486', New England Journal of Medicine, vol. 316, no. 4, pp. 187-191. https://doi.org/10.1056/NEJM198701223160404
Nieman LK, Choate TM, Chrousos GP, Healy DL, Morin M, Renquist D et al. The Progesterone Antagonist RU 486. New England Journal of Medicine. 1987 Jan 22;316(4):187-191. https://doi.org/10.1056/NEJM198701223160404
Nieman, Lynnette K. ; Choate, Teresa M. ; Chrousos, George P. ; Healy, David L. ; Morin, Martin ; Renquist, David ; Merriam, George R. ; Spitz, Irving M. ; Bardin, C. Wayne ; Baulieu, Etienne Emile ; Loriaux, Donald (Lynn). / The Progesterone Antagonist RU 486. In: New England Journal of Medicine. 1987 ; Vol. 316, No. 4. pp. 187-191.
@article{2ef574cdd3c3402bad34c51fe2c2fa5c,
title = "The Progesterone Antagonist RU 486",
abstract = "Since progesterone supports endometrial nidation of the fertilized ovum, a progesterone antagonist would theoretically block this process and thus have contraceptive potential. We have explored the ability of RU 486, a newly developed competitive progesterone antagonist, to function as a contraceptive agent. A single oral dose of 10 mg per kilogram of body weight given in the midluteal phase consistently induced menses within 72 hours in women with normal cycles and no risk of pregnancy. Bleeding was not prevented by administration of human chorionic gonadotropin in the midluteal phase. This suggested that giving a single dose of RU 486 late in the menstrual cycle might be an effective contraceptive strategy. This concept was tested in monkeys. When given to rhesus females on day 25 of the cycle, a single intramuscular dose of RU 486 (5 mg per kilogram) prevented pregnancy. The vehicle-treated control animals had a 28 percent pregnancy rate (P<0.05 by chi-square analysis). No side effects were noted in women or monkeys. These data suggest that a progesterone antagonist such as RU 486 has the potential to be an effective, safe, and convenient contraceptive agent. Further work will be necessary to assess the safety of long-term monthly administration and to define the optimal dose and time of administration in women. (N Engl J Med 1987; 316:187–91.), A SAFE, convenient, and effective method of fertility control has been sought for centuries. No currently available form of birth control, however, is ideal. Oral steroidal contraceptives must be taken daily for maximal effectiveness, and unacceptable side effects increase both with age and with tobacco use.1,2 Intrauterine devices are associated with pelvic inflammatory disease and subsequent decreased fertility.3,4 Barrier methods (condom and diaphragm), although largely free of untoward side effects, have high failure rates related mainly to poor compliance.5 Since progesterone is necessary for nidation of the fertilized ovum, a progesterone antagonist, in theory, could interrupt the hormonal support of…",
author = "Nieman, {Lynnette K.} and Choate, {Teresa M.} and Chrousos, {George P.} and Healy, {David L.} and Martin Morin and David Renquist and Merriam, {George R.} and Spitz, {Irving M.} and Bardin, {C. Wayne} and Baulieu, {Etienne Emile} and Loriaux, {Donald (Lynn)}",
year = "1987",
month = "1",
day = "22",
doi = "10.1056/NEJM198701223160404",
language = "English (US)",
volume = "316",
pages = "187--191",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - The Progesterone Antagonist RU 486

AU - Nieman, Lynnette K.

AU - Choate, Teresa M.

AU - Chrousos, George P.

AU - Healy, David L.

AU - Morin, Martin

AU - Renquist, David

AU - Merriam, George R.

AU - Spitz, Irving M.

AU - Bardin, C. Wayne

AU - Baulieu, Etienne Emile

AU - Loriaux, Donald (Lynn)

PY - 1987/1/22

Y1 - 1987/1/22

N2 - Since progesterone supports endometrial nidation of the fertilized ovum, a progesterone antagonist would theoretically block this process and thus have contraceptive potential. We have explored the ability of RU 486, a newly developed competitive progesterone antagonist, to function as a contraceptive agent. A single oral dose of 10 mg per kilogram of body weight given in the midluteal phase consistently induced menses within 72 hours in women with normal cycles and no risk of pregnancy. Bleeding was not prevented by administration of human chorionic gonadotropin in the midluteal phase. This suggested that giving a single dose of RU 486 late in the menstrual cycle might be an effective contraceptive strategy. This concept was tested in monkeys. When given to rhesus females on day 25 of the cycle, a single intramuscular dose of RU 486 (5 mg per kilogram) prevented pregnancy. The vehicle-treated control animals had a 28 percent pregnancy rate (P<0.05 by chi-square analysis). No side effects were noted in women or monkeys. These data suggest that a progesterone antagonist such as RU 486 has the potential to be an effective, safe, and convenient contraceptive agent. Further work will be necessary to assess the safety of long-term monthly administration and to define the optimal dose and time of administration in women. (N Engl J Med 1987; 316:187–91.), A SAFE, convenient, and effective method of fertility control has been sought for centuries. No currently available form of birth control, however, is ideal. Oral steroidal contraceptives must be taken daily for maximal effectiveness, and unacceptable side effects increase both with age and with tobacco use.1,2 Intrauterine devices are associated with pelvic inflammatory disease and subsequent decreased fertility.3,4 Barrier methods (condom and diaphragm), although largely free of untoward side effects, have high failure rates related mainly to poor compliance.5 Since progesterone is necessary for nidation of the fertilized ovum, a progesterone antagonist, in theory, could interrupt the hormonal support of…

AB - Since progesterone supports endometrial nidation of the fertilized ovum, a progesterone antagonist would theoretically block this process and thus have contraceptive potential. We have explored the ability of RU 486, a newly developed competitive progesterone antagonist, to function as a contraceptive agent. A single oral dose of 10 mg per kilogram of body weight given in the midluteal phase consistently induced menses within 72 hours in women with normal cycles and no risk of pregnancy. Bleeding was not prevented by administration of human chorionic gonadotropin in the midluteal phase. This suggested that giving a single dose of RU 486 late in the menstrual cycle might be an effective contraceptive strategy. This concept was tested in monkeys. When given to rhesus females on day 25 of the cycle, a single intramuscular dose of RU 486 (5 mg per kilogram) prevented pregnancy. The vehicle-treated control animals had a 28 percent pregnancy rate (P<0.05 by chi-square analysis). No side effects were noted in women or monkeys. These data suggest that a progesterone antagonist such as RU 486 has the potential to be an effective, safe, and convenient contraceptive agent. Further work will be necessary to assess the safety of long-term monthly administration and to define the optimal dose and time of administration in women. (N Engl J Med 1987; 316:187–91.), A SAFE, convenient, and effective method of fertility control has been sought for centuries. No currently available form of birth control, however, is ideal. Oral steroidal contraceptives must be taken daily for maximal effectiveness, and unacceptable side effects increase both with age and with tobacco use.1,2 Intrauterine devices are associated with pelvic inflammatory disease and subsequent decreased fertility.3,4 Barrier methods (condom and diaphragm), although largely free of untoward side effects, have high failure rates related mainly to poor compliance.5 Since progesterone is necessary for nidation of the fertilized ovum, a progesterone antagonist, in theory, could interrupt the hormonal support of…

UR - http://www.scopus.com/inward/record.url?scp=0023140098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023140098&partnerID=8YFLogxK

U2 - 10.1056/NEJM198701223160404

DO - 10.1056/NEJM198701223160404

M3 - Article

C2 - 3796691

AN - SCOPUS:0023140098

VL - 316

SP - 187

EP - 191

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 4

ER -